Dr. Mark Shlomchik is a UPMC Endowed Distinguished Professor and Chair of the Department of Immunology at the University of Pittsburgh. He is also a Founder and Chief Scientific Officer of BlueSphere Bio, a company working to create individualized T cell therapies for the treatment of cancer. Dr. Shlomchik’s lab focuses on systemic autoimmune diseases, long-lived B cell immunity, and immunopathogenesis. He talks about the role of toll-like receptors in lupus, how his autoimmune disease research led to potential cancer therapies, and starting a biotech company with his brother.
Read More
Dr. Michael Alonso is a Scientific Co-Founder, and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in “eat me” signals, considerations for moving drugs into the clinic, and building teams in biotech.
Read More
Dr. Anil Bhushan is a Professor at the University of California, San Francisco School of Medicine and Co-Founder of Deciduous Therapeutics, an aging therapeutics company developing a novel class of immune-modulatory therapies. His lab focuses on understanding how the immune system senses and tunes its response to senescent cells in disease and aging and was one of the first to show the role of clearing senescent cells in models of type 1 diabetes.
Read More
Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, a San Francisco and Seattle-based company leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system back to its balanced, fully functioning state.
Read More
Dr. Christopher Klebanoff is an Principal Investigator and Attending Physician at the Memorial Sloan Kettering Cancer Center. His research focuses on cell-based cancer immunotherapies, T cell receptors, and the therapeutic targeting of shared cancer neoantigens. Using single-cell sequencing, biophysical measurements of T cell receptor affinity, genetic engineering, and structural immunobiology, the Klebanoff lab aims to adapt adoptive T cell transfer for advanced solid tumors.
Read More